NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NNVC

NanoViricides Inc

Jun 23 • 04:00PM ET

1.37

Dollar change -0.06
Percentage change -4.20	%

Healthcare • Biotechnology • USA • AMEX

Peers: PFE MRNA BNTX GILD NVAX ADMA VXRT ALT GOVX AIM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.70	Insider Own	3.63%	Shs Outstand	16.07M	Perf Week	-9.27%
Market Cap	22.02M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.49M	Perf Month	-6.16%
Enterprise Value	19.48M	PEG	-	EPS next Q	-	Inst Own	9.26%	Short Float	0.87%	Perf Quarter	5.38%
Income	-9.73M	P/S	-	EPS this Y	-	Inst Trans	2.08%	Short Ratio	0.84	Perf Half Y	-8.05%
Sales	0.00M	P/B	2.49	EPS next Y	-	ROA	-90.50%	Short Interest	0.13M	Perf YTD	-4.20%
Book/sh	0.55	P/C	8.67	EPS next 5Y	-	ROE	-99.84%	52W High	2.55 -46.27%	Perf Year	-16.46%
Cash/sh	0.16	P/FCF	-	EPS past 3/5Y	4.78% 21.52%	ROIC	-110.12%	52W Low	0.94 45.74%	Perf 3Y	-31.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.19% 5.97%	Perf 5Y	-80.14%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.83%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-96.58%
Dividend Ex-Date	-	Quick Ratio	2.27	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.39	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.27	EPS Q/Q	12.13%	SMA20	-9.81%	Beta	0.91	Target Price	6.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-2.40%	Rel Volume	0.88	Prev Close	1.43
Employees	7	LT Debt/Eq	0.00	Earnings	-	SMA200	-0.65%	Avg Volume	161.25K	Price	1.37
IPO	Aug 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-240.00% -	Trades		Volume	141,956	Change	-4.20%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-15	Initiated	Midtown Partners	Strong Buy	$5.30

Jun-18-25 06:30AM	With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
Jun-04-25 06:55AM	NanoViricides Measles Drug Development Animal Study is Imminent (ACCESSWIRE) +6.80%
May-28-25 06:30AM	NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 (ACCESSWIRE)
May-22-25 06:30AM	The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
May-16-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu (ACCESSWIRE) +7.63%
05:16PM	Loading…
May-15-25 05:16PM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
May-14-25 06:30AM	Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution (ACCESSWIRE)
May-08-25 06:30AM	Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo (ACCESSWIRE) +13.71%
May-05-25 06:30AM	NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC (Newsfile)
Apr-29-25 06:30AM	Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It (ACCESSWIRE)
Mar-11-25 06:30AM	NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company (ACCESS Newswire) +11.21%
Mar-04-25 06:30AM	Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan (ACCESS Newswire)
Feb-19-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report (ACCESS Newswire)
Feb-14-25 04:37PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
11:29AM	Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? (Insider Monkey)
06:30AM	Loading…
Feb-11-25 06:30AM	NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape (ACCESS Newswire)
Jan-29-25 06:30AM	NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025 (ACCESS Newswire)
Jan-27-25 06:30AM	NanoViricides Engages CRO for Phase II Clinical Trial (ACCESS Newswire)
Jan-13-25 06:30AM	NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 (ACCESSWIRE) -10.37%
Jan-08-25 06:30AM	Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals (ACCESSWIRE) -9.15%
Dec-23-24 06:30AM	NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape (ACCESSWIRE)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire)
Nov-15-24 06:30AM	NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID (ACCESSWIRE) -8.21%
Nov-14-24 07:20PM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Nov-04-24 12:00AM	NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am (ACCESSWIRE)
Oct-22-24 06:30AM	NanoViricides President Dr. Diwan to Present at the PODD Conference (ACCESSWIRE)
Oct-15-24 06:30AM	NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology (ACCESSWIRE)
Oct-14-24 01:30PM	NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy (Insider Monkey)
Oct-08-24 06:30AM	NanoViricides to Present at the Global AMR Summit 2024 Tomorrow (ACCESSWIRE)
Sep-30-24 06:30AM	NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID (ACCESSWIRE)
06:30AM	Loading…
Sep-26-24 06:30AM	NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including Trojan Horse Drugs (ACCESSWIRE) +5.19%
Aug-26-24 07:30AM	MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX (ACCESSWIRE) +5.26%
Aug-19-24 06:30AM	NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -?A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections (ACCESSWIRE) -5.07%
Aug-08-24 06:30AM	NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
Aug-02-24 07:00AM	Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses? (Newsfile)
Aug-01-24 06:30AM	"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides (ACCESSWIRE)
Jul-24-24 06:30AM	COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides (ACCESSWIRE)
Jul-11-24 06:30AM	A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides (ACCESSWIRE)
Jun-26-24 10:34AM	NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model (News Direct)
Jun-24-24 06:00AM	A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides (ACCESSWIRE) +5.49%
Jun-20-24 06:30AM	A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model (ACCESSWIRE) +23.78%
Jun-11-24 06:30AM	Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect (ACCESSWIRE) +9.24%
Jun-04-24 06:30AM	The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect (ACCESSWIRE)
May-29-24 06:30AM	A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More (ACCESSWIRE) +10.45%
May-23-24 06:30AM	NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc. (ACCESSWIRE)
May-20-24 06:30AM	Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure (ACCESSWIRE)
May-15-24 06:58AM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -20.35%
06:30AM	NanoViricides Has Filed its Quarterly Report (ACCESSWIRE)
May-14-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against RSV (ACCESSWIRE) +24.18%
May-10-24 06:30AM	NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City (ACCESSWIRE)
May-08-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox (ACCESSWIRE) +20.83%
May-06-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against Influenza A (ACCESSWIRE) +23.89%
May-02-24 06:30AM	3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace) +6.19%
Apr-30-24 06:30AM	NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon (ACCESSWIRE) +6.19%
Feb-15-24 06:30AM	NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon (ACCESSWIRE)
Feb-14-24 05:11PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-01-24 06:20AM	Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Jan-29-24 06:30AM	Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found (ACCESSWIRE) +9.35%
Jan-04-24 06:30AM	NanoViricides to Present at the Biotech Showcase in San Fransisco (ACCESSWIRE) +5.83%
Nov-29-23 01:32PM	NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 (News Direct)
Nov-28-23 06:40AM	The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides (ACCESSWIRE) +13.73%
Nov-15-23 06:45AM	NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications (ACCESSWIRE) -9.70%
05:04AM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Nov-14-23 06:45AM	Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development (ACCESSWIRE) +11.67%
Oct-16-23 06:45AM	NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV (ACCESSWIRE)
Oct-12-23 06:45AM	NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET (ACCESSWIRE)
Sep-27-23 08:45AM	Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant (News Direct)
Sep-05-23 06:49AM	NNVC: NanoViricides Begins Clinical Trial of NV-CoV-2 (Zacks)
Aug-31-23 08:00AM	NanoViricides progressing well with new Covid study (News Direct)
Aug-21-23 06:45AM	The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides (ACCESSWIRE) +7.75%
Jul-19-23 09:15AM	SARS-CoV-2 Is Not Done Yet Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? (News Direct)
Jul-13-23 08:31AM	NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst (News Direct) -8.81%
Jul-11-23 09:25AM	Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials What Other Viruses Could This COVID Treatment Target? (News Direct) +10.64%
06:45AM	Companys Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides (ACCESSWIRE)
Jul-06-23 09:00AM	NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment (News Direct)
06:45AM	Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs (ACCESSWIRE)
Jun-29-23 03:00PM	NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2 (News Direct)
06:45AM	NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun (ACCESSWIRE)
Jun-07-23 08:56PM	The 7 Most Promising Penny Stocks to Buy in June (InvestorPlace)
May-31-23 06:40AM	NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET (ACCESSWIRE)
May-16-23 06:54AM	NanoViricides: Fiscal Q3 Earnings Snapshot (AP Finance) -5.36%
06:45AM	NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin (ACCESSWIRE)
May-04-23 06:45AM	NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City (GlobeNewswire)
Apr-25-23 06:45AM	NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient (ACCESSWIRE)
Apr-17-23 06:45AM	NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate (ACCESSWIRE) +21.64%
Apr-12-23 01:59PM	NanoViricides using unique technology platform to fight against viruses (News Direct)
Apr-10-23 08:01AM	NNVC: NanoViricides Technology Ready to Enter the Clinic (Zacks Small Cap Research) -9.70%
Apr-04-23 07:45AM	NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates (ACCESSWIRE) +23.85%
Mar-31-23 11:15AM	COVID Remains A Global Threat NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All (News Direct)
Mar-20-23 09:45AM	A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats (News Direct)
Mar-08-23 10:45AM	With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It (News Direct)
Feb-15-23 06:30AM	NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials (ACCESSWIRE)
Jan-04-23 06:35AM	NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT (ACCESSWIRE) +11.50%
Dec-05-22 06:45AM	NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET (ACCESSWIRE)
Nov-15-22 06:45AM	NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage (ACCESSWIRE)
Oct-28-22 02:49PM	7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov. (InvestorPlace)
Oct-27-22 09:25AM	This Company Is Looking For A Monkeypox Drug As City Investigates Deaths (News Direct)
Oct-14-22 06:40AM	NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage (ACCESSWIRE)
Sep-19-22 09:26AM	NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly (News Direct) -7.73%

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NNVC

NanoViricides Inc

Upgrade your FINVIZ experience